. Calibration curves of antiangiogenic RTKIs. Drugs were dissolved and diluted in 50% methanol in the concentration range of 0.001-0.5 μmol·mL−1. 0.5 µL of the compound solution was applied on the control tumor tissue surfaces. Spraying and detection conditions were the same as those during the analysis of in vivo-treated tumors. Average signal intensities of the applied concentrations were measured and normalized to Total Ion Current (TIC) by using Xcalibur v 2.0.7. and ImageQuest™ softwares.
. Overview of serial frozen tumor sections cut for MALDI-MS imaging, HE staining and immunofluorescence microscopy. Sections #1-4 were immunolabeled with antibodies directed against FGFR1, PDGFRα, PDGFRβ or VEGFR2. MALDI-MS imaging and subsequent HE staining were performed in sections #5 and #7. Section #6 was used for pimonidazole staining (hypoxia detection). Immunostainings for endothelial basement membrane (anti-laminin antibody) and pericytes (anti-desmin and anti-α-smooth muscle actin antibodies) were performed in sections #8, #9 and #10, respectively. Note that areas of necrotic tissue can also appear green due to non-specific binding of the secondary antibody in immunostained sections. Figure S3 . Co-localization of drug compounds (as visualized by MALDI-MSI) and tumor necrosis in C26 tumors treated with motesanib, pazopanib and sunitinib. Asterisks mark intratumoral areas of necrotic tissue in H&E sections (left). In Hoechst nuclear-counterstained sections (middle) these areas (asterisks) appear black due to lack of nuclear counterstain (Hoechst33342, blue). Tumor boundaries are delineated with white line in MALDI-MS images (right). 
